SELL and melanoma: Indeed, tdLN-targeted vaccination with Dexo(B16 + pIC) resulted in reduced tumor growth and prolonged survival of tumor-bearing mice, associated with significantly higher frequencies of melanoma-specific cytotoxic CD8+ T cells and of CD62L-CD44+ effector memory CD8+ T, NK and NK-T cells and lower frequencies of PD-1+ exhausted CD8+ T cells infiltrating the tumors as compared to all the other Dexo vaccine formulations we tested (Figs 5 and 6).